Focused On-demand Library for Ribosomal oxygenase 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8IUF8

UPID:

RIOX2_HUMAN

Alternative names:

60S ribosomal protein L27a histidine hydroxylase; Bifunctional lysine-specific demethylase and histidyl-hydroxylase MINA; Histone lysine demethylase MINA; MYC-induced nuclear antigen; Mineral dust-induced gene protein; Nucleolar protein 52; Ribosomal oxygenase MINA

Alternative UPACC:

Q8IUF8; D3DN35; Q6AHW4; Q6SKS0; Q8IU69; Q8IUF6; Q8IUF7; Q96C17; Q96KB0

Background:

Ribosomal oxygenase 2, known as Ribosomal oxygenase MINA, plays a dual role in cellular mechanisms, acting as a histone lysine demethylase and a ribosomal histidine hydroxylase. It is pivotal in the demethylation of 'Lys-9' on histone H3, enhancing ribosomal RNA expression, and in the hydroxylation of 60S ribosomal protein L27a. This protein is crucial for cell growth and survival, contributing to ribosome biogenesis during pre-ribosomal particle assembly.

Therapeutic significance:

Understanding the role of Ribosomal oxygenase 2 could open doors to potential therapeutic strategies, offering insights into novel approaches for targeting diseases through modulation of gene expression and protein synthesis.